Care Individualized - A program from Merck Oncology

Tools for patients

Choose the teaching and reminder tools that work best for patients in your practice.
To order hard copies of any tool, click here for the online order form.
To download and personalize a tool (or to view a sample PDF copy), just click on the icon or the title of the tool.

Before prescribing EMEND^® (aprepitant) or EMEND^® (fosaprepitant dimeglumine) for Injection, please read the Prescribing Information available by clicking the links below.

“When to Call” instructions Personalize every patient’s instructions by selecting the specific symptoms you want to know about stat.	CINV Risk Assessment Tool Helps you determine individual risk of CINV. Read more or download now.	Personal Health Diary and Monthly Planner Here is a central place for patients to keep track of their chemo and side effects; helps encourage communication between patients and their oncology teams.
Prescription instructions for patients This is a handy reminder and informational sheet for patients prescribed EMEND^® (aprepitant).	iChemoDiary An interactive diary in a portable application that helps track and report common symptoms of chemotherapy! Read more or download now.	Nutrition during chemotherapy This patient-friendly fact sheet explains changing nutritional needs during cancer.
Pocket Diary Cards These are simple enough to help patients keep track of symptoms and portable enough for patients to carry to every appointment.	Bookmark Handy and attractive, bookmarks help patients find what they need (or want) to remember.	Kemo Shark Comic Book Designed to help children understand what happens when a parent undergoes chemotherapy. Written by a child psychologist (and breast cancer survivor).

EMEND and EMEND for Injection, in combination with other antiemetic agents, are indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin; and for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Selected Important Risk Information

EMEND, when administered orally, is a moderate cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly converted to aprepitant, neither drug should be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.

EMEND should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4. Inhibition of CYP3A4 by EMEND could result in elevated plasma concentrations of these concomitant medications. Conversely, when EMEND is used concomitantly with another CYP3A4 inhibitor, aprepitant plasma concentrations could be elevated.

Because a small number of patients in clinical studies received the CYP3A4 substrates vinblastine, vincristine, or ifosfamide, particular caution and careful monitoring are advised in patients receiving these agents or other chemotherapy agents metabolized primarily by CYP3A4 that were not studied.

The most frequent adverse events reported in clinical trials of EMEND for highly emetogenic chemotherapy were asthenia/fatigue (17.8%), nausea (12.7%), hiccups (10.8%), constipation (10.3%), diarrhea (10.3%), and anorexia (10.1%).

The most frequent adverse events reported in clinical trials of EMEND for moderately emetogenic chemotherapy were alopecia (24.0%), fatigue (21.9%), headache (16.4%), constipation (12.3%), neutropenia (8.9%), dyspepsia (8.4%), stomatitis (5.3%), hot flush (3.0%), and pharyngolaryngeal pain (3.0%).

The most frequent clinical adverse events reported in patients receiving EMEND for Injection were infusion site pain (7.6%), headache (3.0%), and infusion site induration (1.5%).